Sort   by:  
 Page size 
ProteomicsAn Unbiased Strategy for Selecting Effective Combinations of Therapeutic Targets Supports the Development of a Novel Bispecific Antibody with Tumor-Suppressing Properties
Recent progress in dissecting molecular mechanisms essential for the survival and propagation of cancer cells triggered rapid development of targeted therapies. Although many of these therapies produce impressive initial responses in tumor suppression, the onset of resistance is practically unavoida...
ORGANISM(S): Homo sapiens (Human) 
2023-01-27 | PXD023034 | Pride
Bispecific anti-egfr/epha2 antibody  epha2 receptor  bioid  proximity proteomics 
GenomicsA Multipronged Unbiased Strategy Guides the Development of an anti-EGFR/EPHA2 Bispecific Antibody for Combination Cancer Therapy
A Multipronged Unbiased Strategy Guides the Development of an anti-EGFR/EPHA2 Bispecific Antibody for Combination Cancer Therapy
PRJNA721399 | ENA
OtherA Multipronged Unbiased Strategy Guides the Development of an anti-EGFR/EPHA2 Bispecific Antibody for Combination Cancer Therapy
Purpose: Accumulating analyses of pro-oncogenic molecular mechanisms triggered a rapid development of targeted cancer therapies. Although many of these treatments produce impressive initial responses, eventual resistance onset is practically unavoidable. One of the main approaches for preventing thi...
ORGANISM(S): Homo sapiens 
2023-02-23 | GSE171920 | GEO
ProteomicsHuman adenocarcinoma cell line for phosphoproteomics
Bispecific anti-EGFR/EPHA2 antibody displays strong tumor-suppressing activity
ORGANISM(S): Homo sapiens (Human) 
2023-01-30 | PXD023087 | Pride
Human Cancer Phosphoproteomics Lcmsms 
UnknownA Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.
Not available
S-EPMC10345963 | biostudies-literature
Sort   by:  
 Page size